Chemomab Therapeutics Ltd. (CMMB) has released an update.
Chemomab Therapeutics Ltd. reports a successful first quarter with early completion of their CM-101 Phase 2 trial in PSC, promising topline data by mid-2024 and additional data in late 2024 or early 2025. The company confirms the significant role of CCL24 in fibrotic diseases through new publications and strengthens its patent portfolio globally. Despite a decrease in R&D expenses, the biotech firm maintains a solid cash position to fund operations into the next year.
For further insights into CMMB stock, check out TipRanks’ Stock Analysis page.
